Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Thromboembolism, anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease Clinical selection for Recombinant Hirudin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
The dosage is determined by the activated partial thromboplastin time (aPTT) ratio. In the case of the aPTT ratio of less than 1.5, the infusion rate is increased in increments of 20%, with the determination of the aPTT ratio 4 hours after each increase.
allergic reaction, anti-hirudin antibodies, intracranial bleeding, bleeding complications, hematuria, anemia, vaginal bleeding, heart failure, nosebleed, and GI bleeding.
Store as labelled. Keep out of reach of children.